RKLB › analyze
RKLB · Analyze
2026-08-27 · $67.53 · Mkt cap $43.2B · EV ~$40.8B · −55.3% off the $151.00 high
A portfolio-specific passage was removed from the public build.
VERDICT — [4.5] WATCH. Do not add. No entry exists above $40.
This is a genuinely good and genuinely improving business attached to a price that requires two unproven things and one uncontracted thing to all work.
What is real: revenue +62% YoY, gross margin 32.1% → 38.2% across four quarters with 53% incremental gross margin, a $2.356B backlog of which ~$1.83B is signed US defence work, prime-contractor status on an $816M SDA award, and a coherent ~$470M acquisition strategy that bought supply-chain bottlenecks rather than revenue.
What is not: Neutron has slipped five times in five years and the sixth slip is already being pre-announced by the CEO. The company burned $187.5M of free cash flow in H1 while issuing $1.53B of stock. And it has agreed to buy Iridium for $8.0B on a $3.6B bridge, taking net debt from −$2.4B to +$3–4B — a deal whose headline synergy is that the unflown rocket will cheaply replace Iridium's constellation.
Every load-bearing element of this story routes back through a rocket that has not flown.
1. FUNDAMENTALS
TTM = Q3 2025 through Q2 2026.
| $M | Q2'25 | Q3'25 | Q4'25 | Q1'26 | Q2'26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 144.5 | 155.1 | 179.7 | 200.3 | 234.1 | 769.1 |
| Gross profit | 46.4 | 57.3 | 68.2 | 76.5 | 84.6 | 286.6 |
| Gross margin | 32.1% | 37.0% | 38.0% | 38.2% | 36.1% | 37.3% |
| Operating income | −59.6 | −59.0 | −51.0 | −56.0 | −57.5 | −223.5 |
| Net loss | −66.4 | −18.3 | −52.9 | −45.0 | −49.3 | −165.5 |
| Adjusted EBITDA | — | — | — | −11.8 | −8.8 | — |
Q2 2026 segment split: Space Systems $189.5M (+38.6% QoQ, 81% of revenue); Launch Services $44.6M (−30% QoQ). The launch decline is an accounting change — a shift to over-time revenue recognition on HASTE — not lost demand, but it does mean the launch line is no longer a clean read on cadence.
The good number
Incremental gross margin, Q1'25 → Q1'26: (76.5 − 35.2) ÷ (200.3 − 122.6) = 53.0%, against a 36.6% average. Per the inverse of [[pattern-incremental-margin-below-average-locks-in-decay]], incremental margin above average is real operating leverage arriving at the gross line. This is the single best fact about the company and it is not in dispute.
The number that cancels it
Operating loss has been flat at −$51M to −$60M for five straight quarters while revenue grew 62%. Gross profit grew $38.2M year-on-year in Q2; operating expenses grew about as much. R&D went $55.1M → $80.5M (+46%) — that is Neutron. All the gross-line leverage is being consumed below the gross line, and adjusted EBITDA loss is guided to widen in Q3 (−$8.8M → −$17 to −$23M).
Cash and the funding model
| H1 2026 | H1 2025 | |
|---|---|---|
| Operating cash flow | −$134.4M | −$77.5M |
| Capex | $53.1M | $60.7M |
| Free cash flow | −$187.5M | −$138.2M |
| Gross ATM proceeds | $1,529.6M | $396.6M |
They raised roughly eight times what they burned. Liquidity at 30 June: cash $2.129B plus $258.1M of securities = $2.387B. Total liabilities $695.2M; equity $3.492B. Convertible notes are down to a $13.1M net carrying amount against $280.8M fair value — the ~$355M issue has essentially all converted to equity, which is a clean outcome and removes the convert overhang.
Runway is not the question. Ownership is.
Dilution — the real story of 2026
| Dec 31 2025 | Jun 30 2026 | Q3'26 guide | |
|---|---|---|---|
| Common outstanding | 543.6M | 598.2M | — |
| Series A preferred | 46.0M | 41.0M | ~41M |
| Total | 589.5M | 639.1M | 641M |
| Additional paid-in capital | $2.736B | $4.607B | — |
+54.6M shares in six months — about 10% dilution in a single half-year, with paid-in capital up $1.87B.
The ATM escalation is the tell:
| Agreement | Size | Status |
|---|---|---|
| Mar 2025 | $750M | $396.6M drawn, terminated |
| Mar 17 2026 | $1.0B | terminated |
| May 20 2026 | $3.0B | $1,055.6M sold, terminated |
| Aug 13 2026 | $1.944B remainder | Live, and rolled to the Iridium bridge lenders (Deutsche Bank, Wells Fargo) |
That last detail is not cosmetic. The same two banks hold both the $3.6B acquisition bridge and the $1.94B ATM. That is how a bridge gets taken out with equity. Expect the ATM drawn hard between now and mid-2027.
There is also 7,451,200 shares of collared forward sales settling April 2028 (~$474–642M expected proceeds) — dilution already sold into the market but not yet in the count.
To be fair: issuing equity at $100–150 during the run to build a $2.4B war chest was correct capital allocation, and converting away a $355M liability was a good outcome. The criticism is not that they raised. It is that per-share value is being diluted ~10% every six months while the operating business still burns ~$110M a quarter, and the count is going higher.
2. THE IRIDIUM ACQUISITION — now the dominant variable
Announced 2026-06-29. S-4/A filed 2026-08-24. Expected close mid-2027.
| Term | Detail |
|---|---|
| Consideration | $54.00/IRDM share — $27.00 cash + $27.00 stock |
| Enterprise value | ~$8.0B |
| Premium | 24% to the 2026-06-26 close |
| Exchange ratio collar | RKLB ≤$67.50 → 0.4000; $67.50–$112.50 → $27.00 ÷ price; ≥$112.50 → 0.2400 |
| IRDM shares out | 105,963,004 |
| Financing | $3.6B 364-day senior secured bridge (DB + Wells Fargo) plus cash and further debt/equity |
| IRDM debt | Retired at close (~$1.8B) |
⚠️ The stock is sitting on the collar floor. At $67.53 against a $67.50 breakpoint, any further weakness fixes the ratio at 0.4000 and RKLB issues more shares the lower its price goes — the exchange ratio stops protecting it exactly where protection would matter.
The bid history
| Date | RKLB offer | Structure |
|---|---|---|
| Apr 15 2026 | $42.50 | all stock |
| Jun 3 2026 | $52.00 | $15 cash + $37 stock |
| Final | $54.00 | $27 cash + $27 stock |
+27% from first offer to final. In the merger background, Party A offered $41–45 all cash and refused to raise; Party B entered diligence and withdrew without bidding; Party C declined to bid. (Press speculation names AST SpaceMobile and Viasat — unconfirmed in the filing; do not treat as fact.) The documented fact pattern is a determined buyer raising 27% into weak competition.
Pro-forma arithmetic — derived, flagged as such
| At the collar floor ($67.53) | |
|---|---|
| Cash to IRDM holders (106.0M × $27) | $2.86B |
| RKLB shares issued (0.4000) | 42.4M |
| IRDM debt retired | ~$1.8B |
| Total cash requirement | ~$4.7B |
| Pro-forma share count | ~680–700M+ |
| Net debt at close | −$2.4B → +$3–4B |
| Combined EBITDA | ~$450–470M |
| Pro-forma leverage | ~7–9x unless a large slug is equitised |
Iridium contributes 2025 revenue $871.7M with $495M operational EBITDA (57% margin), FY26 guided $480–490M on flat-to-+2% service revenue. Pro forma, Iridium is ~45–47% of combined revenue and more than 100% of combined EBITDA.
Read. Strip the "vertically integrated space powerhouse" language and this is a cash-burning, pre-revenue-rocket launch company buying a mature, slow-growth, 57%-margin satellite operator to acquire an income statement. That is not automatically bad — Iridium's MSS spectrum is genuinely scarce, licensed and defence-relevant, and the multiple does improve dramatically (see §4). But three things temper it:
- The core synergy depends on Neutron. The pitch is "we replace Iridium's ageing constellation cheaply because we launch it ourselves." The launcher has not flown. Until it does, the central economic rationale is a projection.
- They bid against themselves — +27% against a rival capped at $45 and two parties who never bid.
- A year of deal risk carried on a bridge, through a Neutron debut that may or may not happen and may or may not succeed.
Neutron determines the multiple; Iridium determines the balance sheet.
3. NEUTRON — five slips in five years
| Stated | Then-promised first launch | Slip |
|---|---|---|
| Mar 2021 (announcement) | 2024 | baseline |
| 2022–2023 | Mid-2025 | +~12mo |
| 2024 | Late 2025 | +~6mo |
| Nov 10 2025 | On pad Q1 2026, launch ~mid-2026 | +~6mo |
| Jan 21 2026 — stage-1 tank ruptures in hydrostatic test (manufacturing defect in a critical joint) | Q4 2026 | +~6mo |
| Aug 10 2026 (Q2 call) | Q4 2026, but "the window is narrowing"; press reports it may slip to 2027 | pending |
~2.5 years of cumulative delay, and the current target is already being pre-walked-back by the CEO on the earnings call. Beck's own framing: "every rocket CEO is probably inflicted with the same optimism then reality." Prediction markets put ~14% odds on a Neutron launch before 2027.
Program status (company claims): >400 Archimedes hot fires across Stage-1 and vacuum variants, now testing durability and restart margin; Stage 1 in final assembly with structural qualification underway; interstage load testing complete; fairing prepping for integrated assembly at Wallops. The highest-risk remaining milestone — a fully-fuelled integrated static fire on LC-3 — has not happened.
Read. The hardware progress is genuine and broad; 400+ hot fires is a campaign, not a press release. But there is no plausible path where the integrated static fire happens, gets analysed, and is followed by a launch inside four months without something going right that has not yet gone right on this programme. Assume 2027.
Beck's pivot — stop asking about flight 1, ask how fast we get to flight 10 — is simultaneously strategically correct and rhetorically convenient. Correct, because medium-lift is a cadence business. Convenient, because it reframes a fifth schedule miss as investor impatience.
And flight 10 is literally the break-even unit. At a reported $50–55M price and a targeted 40–50% gross margin, Neutron needs roughly 10–12 flights a year (~$500–600M revenue, ~$220M gross profit) to cover the current ~$290M annualised operating expense and turn the company profitable. Falcon 9 took about four years from debut to ten flights in a year. If Neutron flies in 2027, cadence-10 lands 2029–2031. That is the honest horizon on every profitability promise management has made.
4. MOAT — 5.5/10. Real, narrow, and substantially policy-conferred.
Electron: the bear case has had six years and has not worked
| Electron dedicated | SpaceX Transporter rideshare | |
|---|---|---|
| Price | ~$8.4M, recent contracts to ~$9.5M | $350K for 50kg, ~$7,000/kg above |
| Effective $/kg | ~$25,000 | ~$7,000 |
| Orbit | Customer's exact plane and RAAN | Fixed SSO, fixed schedule |
Rideshare is 3.5x cheaper per kilogram, and yet Electron's ASP has risen from ~$7.5M to $8.4–9.5M while cadence rose (13 launches YTD 2026 against 21 in all of FY2025, 100% success, ~87 cumulative flights). You cannot raise price into a market you are losing. These are different products: rideshare sells transport, Electron sells control, and constellation operators replenishing specific planes (iQPS, Synspective, BlackSky), national agencies (JAXA) and responsive-space defence missions pay a 3.5x premium because their business breaks without it.
But it is small. Even at 30 launches a year and $9M, that is ~$270M of revenue. Electron is a moat, not an engine.
The mix has quietly shifted to something better — suborbital defence:
| Contract | Value | Scope |
|---|---|---|
| MACH-TB 2.0 block buy (Mar 2026) | $190M | 20 HASTE hypersonic test flights |
| USSF RSLP Kodiak (Jul 2026) | $266M | Up to 18 suborbital missile-defence launches |
$456M contracted, 100% HASTE success record since 2023, no rideshare substitute, and SpaceX has no interest in the segment.
Space Systems: the best business, and the least discussed
60% of backlog, 81% of Q2 revenue.
| Contract | Value | Status |
|---|---|---|
| SDA Tracking Layer Tranche 3 | $816M | Contracted — as PRIME, 18 satellites, SRR passed |
| Flatellite AMTI (Space Force) | $397M | Contracted |
| GEO satellites w/ Heimdall payload | >$160M | Contracted, 3 satellites |
| Golden Dome | $0 | Not a contract — selected with Raytheon to demonstrate; approved vendor on the SHIELD vehicle |
Contracted defence work: ~$1.83B — more than 75% of the $2.36B backlog and roughly 1.9x FY2026E revenue.
Three structural advantages, and they are real:
- Prime status. The $816M TRKT3 award makes Rocket Lab an SDA prime, competing with Lockheed rather than supplying it. Very few companies have made that jump.
- Independence. Terran Orbital was absorbed by Lockheed; Blue Canyon by RTX. Rocket Lab is now the largest independent Western smallsat manufacturer with its own bus, payloads (Geost), laser comms (Mynaric), mechanisms (Motiv), solar cells and launch vehicle. Nobody else has that stack. York Space is the only true peer and is private.
- Bottleneck ownership. The three acquisitions cost ~$470M combined (Geost $275M, Mynaric $155.3M, Motiv $40M + $20M earnout) and each bought a supply-constrained subsystem rather than revenue. Laser optical terminals are the acknowledged pLEO chokepoint — owning Mynaric means Rocket Lab supplies, or declines to supply, its own competitors. That is the right kind of vertical integration.
Adversarial stress test
As SpaceX: I am the structural threat and it is not close. Falcon 9 lists at ~$67–70M against an estimated ~$15M internal cost. Neutron's $50–55M price sits above my marginal cost by roughly 3.5x. I can drop Falcon 9 to $40M, stay profitable, and delete Neutron's entire commercial price argument the moment it wins anything meaningful. Rocket Lab's only defence is non-price: customers who will not fly on me because they compete with Starlink — a set that after mid-2027 includes Rocket Lab itself, via Iridium — and governments that mandate a second source.
As Relativity (Terran R): first flight targeted 2H 2026, the same window as Neutron, backed by Eric Schmidt's capital. Whoever flies first takes the "credible Falcon 9 alternative" slot.
As Stoke Space (Nova): fully reusable, architecturally more ambitious. A 2028+ threat, low probability, high consequence — if Nova works, Neutron is the partially reusable middle child.
Where the attacks fail: nobody attacks the HASTE near-monopoly, the SDA prime position, or the component business that sells into rivals' satellites.
Verdict on the moat
Neutron is a real business but a weak moat. It is a second source in a market with one dominant, structurally lower-cost incumbent. Its 40–50% target margin survives only in a world where SpaceX chooses not to compete on price. That world may persist — SpaceX is capacity-constrained by Starlink's own manifest and may not care about the marginal medium-lift contract — but the economics are granted, not defended.
The durable moat is elsewhere: HASTE, SDA prime status, bottleneck components, and being the credible non-SpaceX vendor to the US government. That last one is the largest, and it is policy-conferred: the DoD needs a second source and will pay for one. It protects Rocket Lab from exactly the price war it cannot win.
Evergreen: partial. Space Systems and HASTE would survive a decade. Neutron's economics would not survive a determined SpaceX.
5. VALUATION
No dividend, no earnings → Graham, DDM and DYT are all N/A. Graham's radicand is negative (EPS −$0.27). Valuation is EV/sales, sum-of-parts and reverse-DCF only.
⚠️ Vendor traps on this ticker — three, and they all matter.
| Field | Vendor | Truth |
|---|---|---|
EV |
$37.43B | ~$40.8B. Yahoo implies ~$5.8B net cash against an actual $2.37B, and ignores the 41.0M preferred |
PE(fwd) / epsForward |
1,351x / $0.05 | FY2027. epsCurrentYear is −$0.045 — FY2026 is a loss. [[pitfall-vendor-forward-eps-is-the-wrong-fiscal-year]] |
sharesOutstanding |
598.46M | 639.1M with preferred (impliedSharesOutstanding has it right, and market cap uses it) |
D/E 3.83 |
— | Meaningless; total debt is ~$15M |
🚫 Never write a
fwd-basis trim on this ticker.site.pywould compute a dollar level off a $0.05 FY2027 EPS and render nonsense — the same failure mode recorded on MTCH. Use price levels in prose only.
Where the multiple actually is
| EV ÷ TTM revenue ($769.1M) | 53.1x |
| EV ÷ FY2026E revenue (~$977M) | 41.8x |
| EV ÷ EBITDA | negative |
| Pro forma with Iridium — EV ~$48.8B ÷ combined revenue ~$1.85B | ~26.5x |
| Pro forma EV ÷ combined EBITDA (~$460M) | ~106x |
The deal genuinely halves the sales multiple and produces positive EBITDA for the first time. That is the strongest single argument for the acquisition, and it is real. It also buys that with $3–4B of net debt and ~60M shares.
Reverse DCF — what $40.8B of enterprise value requires
| Horizon | Exit EV/Sales | Required revenue | Implied CAGR from $769M |
|---|---|---|---|
| 7 years | 5x | $15.9B | 53.7% |
| 10 years | 5x | $21.2B | 39.4% |
| 10 years | 8x | $13.2B | 33.0% |
For scale: $19–21B of revenue is larger than Lockheed Martin's entire space segment, and roughly the size of the whole Western commercial space market outside SpaceX. The current price asks Rocket Lab to sustain a ~40% compound growth rate for a decade and convert a 37%-gross-margin, −33%-operating-margin business into one worth 5x sales.
Sum of the parts
| Component | Basis | Value |
|---|---|---|
| Space Systems | ~$700–760M FY26 run-rate, 50%+ growth, prime status, at 10–15x sales | $7.0–11.4B |
| Launch (Electron + HASTE) | ~$220–260M, at 10–15x sales | $2.2–3.9B |
| Neutron | Full-success value ~$3.75B, at ~50% probability discounted 4–5 years | $1.2–1.9B |
| Net cash | $2.37B | |
| Total | $12.8–19.6B | |
| Per share (639M) | $20–31 |
On a deliberately generous set (Space Systems at 20x sales, Launch at 15x, Neutron at full undiscounted value) the total reaches ~$25.2B → $39/share.
Fair value
| Scenario | Value | |
|---|---|---|
| Bear | Neutron slips to 2028 or fails on debut; ATM drawn hard; deal leverage bites; SDA restructures | $18–25 |
| Base | Neutron flies 2027 and works, cadence builds slowly; Iridium closes and delevers on schedule; Space Systems compounds | $25–45 |
| Bull | Neutron flies on time and scales; Iridium accretive from day one; Golden Dome converts to contract | $75–100 |
FV range $25–45, central ~$34. Entry $28–36. Strong buy below $24. The 52-week low was $37.57, so the entry zone requires a further ~45% drawdown from spot — but unlike MTCH's case, it is not below anything the stock has ever traded.
At $67.53 the price is roughly 2x my central case, and there is no entry.
Sell side — and why I am so far below it
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20 | BTIG | Hold (downgrade, post-print) | — |
| Aug 17 | Cantor Fitzgerald | Buy | $122 |
| Aug 11 | Needham | Buy | $120 |
| Aug 11 | Morgan Stanley | Overweight | $105 |
| Aug 11 | Craig-Hallum | Buy | $120 |
| Jun 30 | BofA | Buy | $115 |
Consensus Buy, 0 Sells, mean $112.94 (+67%). Short interest 8.10% of float, 2.2 days to cover, falling.
Every target sits 55–80% above spot on a stock 55% off its high. That gap is the sell side still marking to a world in which Neutron flew in 2026. The single most informative rating action is BTIG's Aug 20 downgrade to Hold — the only one issued after both the Q2 print and the "window is narrowing" comment.
My range is materially below the street because I am not capitalising Neutron at full value, not capitalising Golden Dome at all (it is a demonstration selection, not a dollar), and I am using the ~700M post-deal share count rather than today's.
6. SENTIMENT — the insider story is a non-event, and the media has it backwards
Verified against Form 4 XML from EDGAR rather than aggregators.
| Insider | Title | Sold 2026-08-24 | Proceeds | Held after |
|---|---|---|---|---|
| Frank Klein | COO | 45,692 | ~$3.18M | 961,295 |
| M. B. Clevenger | President, Rocket Lab USA | 15,051 | ~$1.05M | 458,924 |
| Adam Spice | CFO | 9,677 | ~$674K | 1,155,967 |
| Arjun Kampani | GC | 7,754 | ~$540K | 256,951 |
| A. Ricupati | VP Controller | 669 | ~$47K | 26,863 |
| Total | 78,843 | ~$5.49M | 2,859,000 |
All five sold on the same day, in the same three price tranches ($69.5345 / $70.2023 / $71.17), pro rata to holdings, and retained 97.3% of their combined position. The H1 cash-flow statement carries a corroborating line: "Proceeds from sale of employees restricted stock units to cover taxes: $151,719K."
This is a company-administered market sell-to-cover on RSU vesting. The "Rocket Lab Insiders Sell $5.5M" headlines are wrong, and so is any screen that reads it as discretionary.
⚠️ This is the mirror image of [[pitfall-yahoo-insider-purchases-counts-rsu-grants]] and needs its own note. A screen that excludes code F to filter out tax withholding would count these as genuine open-market sales, because a market sell-to-cover is coded S, not F. Code F means net share withholding by the issuer; code S means shares hit the tape. The rule: same-day, same-price-tranche, pro-rata sales across multiple officers are a sell-to-cover programme regardless of code — confirm against the cash-flow statement's "RSU sales to cover taxes" line.
Separately — and this part is real. CEO Peter Beck's Equatorial Trust has made three large discretionary dispositions: 2.5M shares @ $48–55 (Sep 2025), 2.5M @ $53–64 (Dec 2025), 3.28M @ $81.59–101.57 (Jul 2026) — roughly $555M. Director Ocko sold 1.87M @ $47–52 and 5.37M @ $17.73; Director Slusky sold repeatedly through 2026 at $115–150. There has never been an open-market purchase by anyone in the record. Beck's trust also converts preferred to common 5M at a time, which is structural, not a sale.
Founder diversification after a 4x run is normal and I do not read it as a signal about the business. But the complete absence of any purchase, ever, by anyone, means there is no insider vote of confidence available to weigh against the price.
One disclosure worth tracking: the 10-Q discloses a delivery delay on a customer programme where the customer may claim liquidated damages, net exposure not currently determinable. MDA Corporation was 11% of accounts receivable at 30 June. That is the kind of line that becomes a charge two quarters later.
7. AGENT TENSIONS
Fundamentals vs Moat — resolved in Moat's favour, with a caveat. Fundamentals argued that five quarters of flat operating loss against 62% revenue growth means the operating leverage is not arriving. Moat rebutted that the flat loss is deliberate — R&D up 46% is Neutron, a discrete programme with an end date, and stripping it would show a profitable Space Systems business. Moat is right that the spend is a choice rather than a structural failure. Fundamentals is right that the choice has been made for five years running against a delivery date that has moved five times. The synthesis is the recheck trigger: this argument is settled by the LC-3 static fire, not by another quarter of income statement.
Valuation vs Sentiment — unresolved, and I have taken a side. Sentiment notes 0 Sells and a $112.94 mean. Valuation cannot reach $67.53 on any set of assumptions that does not credit Neutron at full success and Golden Dome as revenue. I have sided with Valuation and stated plainly that my range is far below the street. The honest caveat is that a 40%-CAGR business with a $2.36B backlog is exactly the kind of name where a sum-of-parts is most likely to be too conservative — the same method would have said no to Nvidia in 2019. That is why the verdict is WATCH with a live entry zone rather than AVOID.
A portfolio-specific passage was removed from the public build.
9. TRIGGERS
The recheck trigger is not a date — it is the LC-3 integrated static fire. That single event resolves more of this thesis than any earnings print will.
Break triggers — any one downgrades toward [3.0] AVOID: - Neutron formally slipping to 2028, or a second hardware failure in qualification - The integrated static fire not happening by 2026-12-31 - Iridium deal terminating, or the bridge repriced/resyndicated on worse terms - Non-GAAP gross margin below 33% for two consecutive quarters (Q3 is guided 35–37%) - Adjusted EBITDA loss widening again in Q4 after the guided Q3 widening - Share count above 720M before the deal closes — i.e. the ATM drawn beyond the deal requirement - The liquidated-damages exposure crystallising as a material charge - Any SDA restructure or cancellation touching TRKT3
Upgrade triggers — toward [6.0], with the entry zone raised: - A successful integrated static fire on LC-3 — this alone is worth a full re-underwrite - Neutron flying successfully, at which point the whole valuation frame changes - Golden Dome converting from a demonstration selection into a signed contract - Iridium closing with more than half the cash leg funded by debt rather than equity - Adjusted EBITDA positive for a quarter without a one-off - Any open-market insider purchase — there has never been one
Recheck: Q3 FY26 print, ~2026-11-10. Watch non-GAAP gross margin against the 35–37% guide, the share count against the 641M guide, and any LC-3 milestone language — not the revenue headline, which the Q3 guide has already given you.
APPENDIX — flagged unverified
- Neutron's contracted price per launch ($50–55M is secondary-source)
- Falcon 9's ~$15M internal cost (industry estimate, not disclosed)
- The identity of Iridium's rival bidders Parties A/B/C — press attributions to AST SpaceMobile and Viasat are speculation, explicitly unconfirmed in the merger filing
- Archimedes qualification detail at Stennis; the barge / landing recovery programme (no public disclosure)
- Any material warrant overhang — absent from the 10-Q, but not affirmatively confirmed as zero
- Q3 quarter-to-date Electron launch count beyond the 13 cited on the August call
- The pro-forma share count, leverage and EV figures in §2 are my arithmetic from the S-4/A terms, not company-disclosed pro formas